What Prasterone Treats: Main Uses and Benefits

Prasterone is commonly used to address conditions presenting with systemic or localized discomfort, specifically those associated with postmenopausal hormonal changes. This therapy is primarily relevant for managing the symptoms of Vulvovaginal Atrophy (VVA) and the Genitourinary Syndrome of Menopause (GSM).

The medication helps manage a symptom cluster that includes moderate to severe painful sexual intercourse (dyspareunia), as well as persistent vaginal dryness, localized soreness, and vulvovaginal irritation. It is applied during phases of increased distress or discomfort, supporting symptoms linked to tissue structure. This approach assists with maintaining functional stability and contributes to easing the overall symptom load related to chronic physical discomfort.

“The treatment may assist with managing symptoms that create noticeable functional strain.”

---

Quick Fact: Use in Painful Sexual Activity Prasterone is generally used when VVA symptoms, particularly dyspareunia, become moderate to severe, and supports general well-being during symptomatic phases.

Regulatory References

1. European Medicines Agency overview

Who can and cannot use Tronolane? — Official Regulatory Information

Tronolane (pramoxine and zinc oxide cream) is generally allowed for use by adults and children 12 years of age and older. All eligibility guidelines are based strictly on regulatory labeling from sources like the FDA.

Contraindicated and Restricted Populations

Classification	Population	Restriction Details
Contraindicated	Individuals with known allergy/hypersensitivity	Must not use the product if allergic to pramoxine, zinc oxide, or any other ingredient in the formulation.
Requires Consultation	Children under 12 years of age	Do not use without first consulting a doctor.
Requires Consultation	Pregnant or breast-feeding individuals	Ask a health professional before use.
Requires Consultation	Individuals with specific concurrent conditions	Ask a doctor before use if you have heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to an enlarged prostate gland (relevant for certain rectal formulations).

Conditions for Stopping Use

Regulatory labeling requires an individual to stop use and consult a doctor if: rectal bleeding occurs; the condition worsens; or the condition does not improve within 7 days.

The official interaction profile for Prasterone is defined by regulatory caution concerning co-administration with other hormone products, due to a lack of formal investigation into these specific combinations. This medicine is an inactive precursor that converts locally to active hormones, which dictates its core interaction constraints.

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Systemic Hormone Replacement Therapy (HRT); Vaginal Oestrogens.
Mechanistic basis of interactions	Increases systemic exposure (Cmax and AUC) of its own metabolites: testosterone, estrone (E1), and estradiol (E2).
Population-specific interaction notes	Caution should be exercised for patients with hepatic impairment.

Interaction Classifications

Classification	Official Regulatory Documentation Statement
Interaction severity classification	Not Recommended (due to uninvestigated combination risk).
Interaction-context constraints	Concomitant use with other hormone products (systemic or vaginal) is not recommended.

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Systemic Hormone Replacement Therapy (including oestrogen, progestogen, or androgen treatment) is not recommended because the safety of concurrent use has not been established.
• The use of Tronolane with Vaginal Oestrogens is similarly not recommended due to a lack of investigation into this combination.
• Administration leads to a documented pharmacokinetic outcome of increased systemic plasma concentrations for the steroid metabolites Testosterone, Estrone, and Estradiol.

Connection to the overall interaction profile: The regulatory profile is structured around the prohibition of co-administration with other hormone therapies. No specific drug-drug interactions involving CYP enzymes, drug transporters, food, or alcohol are explicitly listed in the official interaction sections of the labels.

Localized Hormone Synthesis: Intracrinology and Dual Receptor Agonism

The mechanism of Prasterone is defined by intracrinology, where the inactive molecule is absorbed locally and immediately converted into active hormones—both androgens and estrogens—by specific steroidogenic enzymes within the target cells. This process ensures the active metabolites act as agonists on their respective Androgen (AR) and Estrogen (ER) Receptors, a mechanism that restricts systemic distribution of the converted metabolites.

Cellular Proliferation and Tissue Structural Modulation

The activation of the dual AR and ER system initiates a mechanistic cascade by influencing gene transcription that supports cellular proliferation and differentiation. This signaling promotes the growth and maturation of the basal cells into functional epithelial layers, leading to increased synthesis of structural components and greater tissue distensibility. This cellular process results in greater epithelial cell layering and increased capacity for fluid transfer.

Mechanistic Specificity and Functional Constraints

The mechanism's strict reliance on localized enzyme activity and high local concentration of the pro-drug means the resulting physiological changes (e.g., epithelial thickening, pH modulation) are confined to the targeted tissue. This constraint limits systemic absorption, creating a mechanism confined to the peripheral pathways that results in low systemic contribution to overall hormonal load.

The administration of the active ingredient Prasterone is structured by guidelines that define a non-systemic, localized pattern of use. It is administered as a 6.5 mg vaginal insert (pessary), which is the only approved dosage form and strength for this therapeutic application.

---

Official Administration Guidelines

Feature	Official Administration Guideline
Route of administration	The product is designed for the vaginal (intravaginal) route only.
Dosing schedule	The standard regimen is one (1) vaginal insert of 6.5 mg administered once daily (q.d.).
Timing	The insert must be administered at bedtime to optimize retention and consistency.
Special procedural conditions	The insert can be placed using the provided disposable applicator or with a clean finger.
Missed-dose rules	If a dose is forgotten, it should be taken as soon as remembered. However, if the next scheduled dose is due in less than 8 hours, the missed dose is to be skipped to prevent double dosing.

---

Use Patterns and Adjustments

The pattern of use is continuous but not automatically long-term. Treatment continuation requires periodic medical re-evaluation, with recommendations for reassessment of risks and benefits at least every 6 months. This conditional duration pattern is a core component of the usage.

For older adults (Geriatric) and individuals with renal or hepatic impairment, it is stated that no dose adjustment is required for the 6.5 mg daily dose, as the medicine acts locally with minimal systemic absorption. The medicine is not indicated for pediatric use.

Research evidence / Overview of studies for Tronolane

The research for Prasterone focuses on its use in postmenopausal women experiencing changes in vaginal tissue health. The body of evidence is primarily composed of short-term, randomized controlled trials (RCTs) that compared Prasterone against a dummy treatment (placebo), alongside longer, open-label studies that monitored patients for up to a year. The research describes patient-reported experiences and the measurement of physiological changes across defined time intervals.

---

Evidence for use in Moderate to Severe Dyspareunia

The core research explored outcomes related to physical discomfort, specifically moderate to severe painful sexual intercourse (dyspareunia). Researchers explored this symptom in postmenopausal women diagnosed with vulvovaginal atrophy (VVA) by conducting several short-term (12-week) randomized, double-blind trials. In these pivotal trials, the main outcome studied was the measurement of a change in the severity score of the patient's Most Bothersome Symptom (MBS), which was observed in these studies as typically dyspareunia.

Research highlights changes measured during the study period, including how symptoms evolved in the observed populations. Research examined the severity of painful sexual activity in the study population and monitored patterns in those who received a placebo. Findings describe patterns observed in the studies and provide insight into short-term changes. However, existing evidence provides limited insight into comparisons against other similar vaginal therapies, as direct comparative evidence is lacking.

---

Evidence for Changes in Vaginal Tissue Health

Research was also conducted to examine objective signs of tissue health, specifically monitoring outcomes that reflect physical discomfort. This involved trials assessing short-term changes in biological markers relevant to vaginal health. The studies monitored changes in vaginal pH (a measure of acidity) and the Vaginal Maturation Index (VMI), which tracks the composition of cells in the vaginal wall. Data show patterns related to shifts in these objective tissue biomarkers. Studies reported that changes were measured in both the VMI and vaginal pH over the 12-week study period.

---

Long-Term Follow-up and Durability of Study Findings

Since VVA is a condition where symptoms may vary in intensity, the safety and monitored outcomes was evaluated in open-label studies that followed groups of women for up to 52 weeks (one year). However, long-term effects are not fully established because evidence for use past the 52-week follow-up durations were limited. Research is ongoing to further contribute to understanding symptom patterns in this patient population.

Key Studies & References

1. Clinical Review - Prasterone (Intrarosa) - NIH Bookshelf (Discusses ERC-238, ERC-231, and ERC-230 trials)
2. DHEA Against Vaginal Atrophy - Safety Study of 12 Months (NCT01256671) - ClinicalTrials.gov

Common questions about Tronolane (FAQ)

Q: What is the active ingredient in Tronolane?

The active ingredient in Tronolane is pramoxine (pramoxine hydrochloride).

---

Q: What is Tronolane used for?

Tronolane, containing pramoxine, is used for the temporary relief of pain and itching associated with certain minor skin irritations. Specifically, it can be used for the temporary relief of pain, itching, burning, and discomfort caused by hemorrhoids and other minor anal irritations.

---

Q: How does Tronolane work?

Pramoxine belongs to a class of medications called local anesthetics. When applied to the affected area, it works by numbing the nerves in the skin. This temporary numbing action helps to block the pain and itch signals, providing temporary relief from discomfort.

---

Q: How should I apply Tronolane for hemorrhoids?

If using Tronolane for hemorrhoids or other anal conditions, the medication is typically applied to the affected area up to 4 to 5 times a day, usually after each bowel movement, or as directed by a healthcare provider. Gently clean and dry the affected area before application.

---

Q: How quickly will I feel relief after using Tronolane?

Because pramoxine is a local anesthetic, its pain- and itch-relieving effect usually begins shortly after application as the active ingredient starts to numb the nerve endings in the affected area.

---

Q: Are there any common side effects of Tronolane?

Most people do not experience serious side effects when using pramoxine as directed. However, in some cases, people may experience mild temporary burning, stinging, or redness at the site of application. If these effects persist or worsen, or if you develop a rash or signs of a serious allergic reaction, stop use and seek medical attention.

---

Q: Can children use Tronolane?

For hemorrhoids or other genital/anal conditions, children under 12 years of age should not use this medication unless directed by a doctor. For minor skin irritations in general, do not use pramoxine on children younger than 2 years unless directed by a doctor.

How to Store and Dispose of Tronolane (Prasterone Vaginal Inserts)

The official labeling mandates specific conditions to ensure the stability of the Prasterone vaginal inserts.

Storage Requirements

Store the medication at temperatures between 5 C and 30 C (41 F and 86 F), which allows for storage at either controlled room temperature or in the refrigerator. It is essential to keep the product in its original, closed container and protect it from excess heat and moisture. Do not freeze the inserts. As a safety measure, the product must be kept out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired medication must not be flushed down the toilet or poured into a drain. The preferred method for discarding is a drug take-back program. If a take-back program is unavailable, follow the official guidelines to mix the product with an undesirable substance, place it in a sealed bag, and dispose of it with household trash.